22 research outputs found
40 – Comparaison interinstitutionnelle de l’impact du Mammaprint sur les taux de sous et surtraitement de la RCP des patientes avec un cancer du sein
Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
Combined use of MammaPrint and molecular subtyping profile (BluePrint) to identify subgroups with marked differences in response to neoadjuvant treatment.
Comparison of MammaPrint, BluePrint, and TargetPrint with clinical parameters in patients with breast cancer: Findings from a prospective United States cohort.
P207 Feasibility of Mammaprint risk assessment using vacuum-assisted breast biopsy (Mammotome) in early breast cancer
P203 Inter-institutional comparison of impact of Mammaprint on the routine treatment decision-making process in early breast cancer patient populations from three European hospitals
European inter-institutional impact study of MammaPrint.
peer reviewedAIM: To measure the impact of MammaPrint on adjuvant treatment decisions and to analyze the agreement in treatment decisions between hospitals from 4 European countries for the same patient cohort. METHODS: Breast cancer patients were prospectively enrolled and MammaPrint was assessed. Patients' clinical data without and then with MammaPrint results were sent to the different multidisciplinary teams and treatment advice was provided for each patient. RESULTS: Using MammaPrint, chemotherapy treatment advice for ER+/HER2- breast cancer patients was changed in 37% of patients by the Dutch, 24% by the Belgian, 28% by the Italian and 35% by the Spanish teams. MammaPrint increased the inter-institutional agreement in treatment advice (chemotherapy or no chemotherapy) from 51% to 75%. CONCLUSION: The results of this study indicate that MammaPrint impacts adjuvant chemotherapy recommendation. MammaPrint can decrease inter-institutional and inter-country variability in adjuvant treatment advice for breast cancer patients